Business Context and Reporting Period
This Form 8-K Current Report was filed by Longeveron Inc. on April 5, 2022, covering events occurring on April 1, 2022. The filing primarily addresses the appointment of a new executive officer and provides notice regarding the upcoming 2022 Annual Meeting of Stockholders.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation details.
Material Changes and Executive Appointment
Longeveron Inc. announced the appointment of K. Chris Min, M.D., Ph.D., as Chief Medical Officer (CMO), effective April 4, 2022. Dr. Min will lead global clinical development and regulatory strategy for the company's investigational products. He brings over a decade of experience in pharma and biotech clinical development, including roles at Enterin Inc., Cerevel Therapeutics, BlueRock Therapeutics, and Merck Research Laboratories.
Compensation Arrangements
- Base Salary: $350,000 annually.
- Performance Bonus: Eligible for up to 30% of base salary, prorated for the first year.
- Signing Bonus: $60,000 total (50% in restricted stock units, 50% in stock options).
- Equity Awards: 150,000 RSUs and stock options for 50,000 shares.
- Vesting Schedule: Equity awards vest one-quarter on the first anniversary, with quarterly vesting thereafter over a four-year period, subject to continued service.
Corporate Governance and Outlook
The Board of Directors has set June 24, 2022, as the date for the 2022 Annual Meeting of Stockholders. Stockholders wishing to submit proposals under SEC Rule 14a-8 must do so by May 6, 2022. For other business or director nominations to be brought before the meeting, notice must be delivered to the Secretary by June 17, 2022.
The filing includes no specific financial guidance, risk factors, or contingencies beyond standard employment agreement terms.
Investor Verification Checklist
- Verify the terms of the Employment Agreement filed as Exhibit 10.1.
- Confirm the vesting schedule and performance conditions for Dr. Min's equity awards.
- Note the deadlines for shareholder proposals (May 6, 2022) and director nominations (June 17, 2022) for the June 24, 2022 Annual Meeting.
- Review the attached press release (Exhibit 99.1) for additional context on the CMO appointment, noting it is not deemed "filed" under Section 18 of the Exchange Act.